The Value of PET Imaging in Patients with Localized Gastroesophageal Cancer.

摘要: Preoperative induction therapy in stages II and III adenocarcinoma of the esophagogastric junction (AEG) gastric cancer is now an accepted treatment choice Western world. Patients who respond to have significantly improved survival compared nonresponding patients. Until recently, however, no prospectively tested markers for predicting response and/or prognosis this settingwere available. The MUNICON I study recently showed utility fluorodeoxyglucose-positron emission tomography (FDG-PET) AEG indicated feasibility a PET-guided algorithm. These findings are important step forward tailoring multimodal tumor biology. In cancer, issue more complicated, because approximately 30% these cancers cannot be visualized with sufficient contrast quantification. Insufficient FDG uptake mostly associated diffusetype signet cells mucinous content. avid patients, FDG-PET can used evaluation. nonavid patients similar metabolic nonresponders. addition new tracers (eg, fluorothymidine) might increase accuracy tests future. types II, feasible will undergo further evaluation randomized multicenter trial. there should consideration such concepts as immediate resection after 2 weeks or without adjuvant nonresponders modified chemotherapy regimens possibly including biologically targeted drugs non-avid tumors.